Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UCB BIOSCIENCES, Inc.
With
Syneos Health
Parexel
Age
18–64
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Pregnancy is identified while the patient is participating in an interventional or noninterventional Certolizumab Pegol (CZP) study conducted by UCB, or a development partner, regardless of phase or treatment arm (ie, commercial or investigational, placebo or comparator treatment), or whose pregnancies were spontaneously reported to UCB due to potential CZP exposure during pregnancy
Sufficient information to classify the pregnancy as prospective or retrospective is available
Full initial reporter (ie, woman or healthcare provider (HCP)) contact information reported to allow for follow-up (name, address, telephone number/email address) and contact information for at least 1 applicable HCP if initial contact is the woman
Consent to participate is provided
You may not be if
Pregnancies in which the resulting infant is over 1 year of age at the time of informed consent will not be eligible to participate in the study
